The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors ribociclib (Kisqali), palbociclib (Ibrance), and abemaciclib (Verzenio) have transformed treatment in breast cancer patients with hormone receptor–positive, HER2-negative disease. But with any new class of agents entering the scene, oncologists are likely to encounter unique challenges such as which patients are appropriate candidates, what toxicities to be aware of with each drug and how to select the right one based on their differing adverse event profiles. There also remain many unanswered questions on integrating these drugs into clinical practice.
The following three-question quiz will test one aspect from each article in a MedPage Today “Clinical Challenges” series on CDK4/6 inhibitors. Correct answers and explanations will appear after completing the quiz.